Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.


Raised to Date: Raised: $95,809

Total Commitments ($USD)



Start Date


Close Date


Min. Goal


Max. Goal


Min. Investment


Security Type

Equity - Common

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Rolling Commitments ($USD)

Reporting Date


Days Remaining
% of Min. Goal


% of Max. Goal


Likelihood of Max
Avg. Daily Raise


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Healthcare & Pharmaceuticals

Tech Sector



Bridgewater, New Jersey

Who Should Be Interested:
Are you, or is someone in your life, impacted by Alzheimer’s? Is so, Neurotez Inc. could be the investment you’ve been looking for. Their highly experienced team is developing a drug to treat Leptin deficiency in Alzheimer’s patients and/or act as a preventative for those who are at risk, and their drug might just be the missing piece needed to help fight this terrible disease.

The Company:
Neurotez Inc. is on a mission to become the world leaders in biotechnology and to help Alzheimer’s patients with drugs that are both safe and efficacious. Their primary goal is to develop a Leptin product as an innovative hormone replacement therapy for Alzheimer’s disease and/or as a preventative for those who are at risk. Today’s medications provide limited relief, and current efforts, which focus on removing either Abeta or tau deposits from the brain, have not generated any effective drugs for the last 18 years. Neurotez is here to change that -- by focusing on Leptin instead and attacking the disease in a new way. So far, Neurotez has been nominated as the Most Promising Private Company in 2015 by the Biotechnology Industry Organization, as well as a 2010 Incubator Company to Watch at the NJTC Gala Awards. Add in that their team has deep experience and success with thousands of publications in Alzheimer’s, and you can see why Neurotez might just be the Alzheimer's weapon we’ve been waiting for.

The Bottom Line:
Neurotez Inc. is changing the game when it comes to treating and fighting Alzheimer’s. Their Leptin product attacks the disease in a new way, and with Alzheimer’s affecting more than five million Americans and 18 million patients worldwide, we need all the help we can get. This innovative treatment might be just what patients need to help with -- or prevent -- the devastating effects of Alzheimer’s.
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Neurotez 01/27/2023 Netcapital $45,272,228 $15,952 Equity - Common Funded RegCF
Neurotez 03/10/2022 StartEngine $44,870,036 $33,845 Equity - Common Funded RegCF
Neurotez 06/24/2021 Netcapital $21,959,058 $255,718 Equity - Common Funded RegCF
Neurotez 02/26/2018 Netcapital $24,544,690 $95,809 Equity - Common Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.
Are you the founder of Neurotez? Create your account today to claim this raise page.

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Neurotez on NetCapital
Platform: Netcapital
Security Type: Equity - Common
Valuation: $24,544,690

Follow company

Follow Neurotez on NetCapital
View on Netcapital (Closed)